Gan & Lee Pharmaceuticals.
SSE:603087.SS
58.9 (CNY) • At close June 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,045.348 | 2,608.037 | 1,712.27 | 3,612.044 | 3,361.882 | 2,895.062 | 2,387.387 | 2,370.529 | 1,771.493 | 1,219.809 | 926.601 | 692.642 |
| Cost of Revenue
| 766.506 | 697.421 | 405.804 | 396.111 | 306.653 | 237.975 | 187.865 | 205.107 | 166.367 | 109.499 | 82.448 | 67.411 |
| Gross Profit
| 2,278.842 | 1,910.616 | 1,306.467 | 3,215.933 | 3,055.229 | 2,657.087 | 2,199.521 | 2,165.423 | 1,605.127 | 1,110.309 | 844.153 | 625.23 |
| Gross Profit Ratio
| 0.748 | 0.733 | 0.763 | 0.89 | 0.909 | 0.918 | 0.921 | 0.913 | 0.906 | 0.91 | 0.911 | 0.903 |
| Reseach & Development Expenses
| 541.045 | 501.022 | 562.469 | 474.589 | 419.985 | 235.555 | 142.991 | 137.047 | 95.877 | 50.082 | 39.75 | 31.404 |
| General & Administrative Expenses
| 115.887 | 90.096 | 84.518 | 97.805 | 99.973 | 66.014 | 59.729 | 58.728 | 230.245 | 144.858 | 148.102 | 106.489 |
| Selling & Marketing Expenses
| 726.294 | 578.13 | 1,086.546 | 1,002.815 | 914.848 | 796.396 | 720.003 | 592.716 | 472.488 | 436.515 | 341.691 | 276.924 |
| SG&A
| 842.181 | 1,122.238 | 1,171.065 | 1,100.62 | 1,014.82 | 862.41 | 779.732 | 651.444 | 702.732 | 581.374 | 489.794 | 383.412 |
| Other Expenses
| 264.075 | -26.632 | 137.207 | 181.161 | 190.665 | 201.334 | -0.564 | -2.315 | 6.89 | 3.643 | 8.149 | 7.71 |
| Operating Expenses
| 1,647.301 | 1,595.33 | 1,870.741 | 1,756.37 | 1,625.471 | 1,299.3 | 1,076.473 | 901.753 | 711.096 | 591.047 | 503.924 | 393.757 |
| Operating Income
| 631.54 | 315.286 | -564.275 | 1,698.911 | 1,452.905 | 1,397.905 | 1,114.087 | 1,269.691 | 900.001 | 522.121 | 347.254 | 233.876 |
| Operating Income Ratio
| 0.207 | 0.121 | -0.33 | 0.47 | 0.432 | 0.483 | 0.467 | 0.536 | 0.508 | 0.428 | 0.375 | 0.338 |
| Total Other Income Expenses Net
| -1.155 | -9.145 | -13.6 | -2.899 | -7.434 | -0.436 | -0.564 | -1.761 | 6.808 | 3.633 | 7.965 | 7.581 |
| Income Before Tax
| 630.385 | 306.141 | -582.473 | 1,696.013 | 1,445.47 | 1,397.469 | 1,113.523 | 1,267.93 | 906.809 | 525.754 | 355.219 | 241.457 |
| Income Before Tax Ratio
| 0.207 | 0.117 | -0.34 | 0.47 | 0.43 | 0.483 | 0.466 | 0.535 | 0.512 | 0.431 | 0.383 | 0.349 |
| Income Tax Expense
| 15.721 | -34.09 | -142.957 | 243.258 | 214.76 | 230.189 | 179.558 | 187.976 | 137.191 | 78.359 | 50.164 | 36.734 |
| Net Income
| 614.664 | 340.069 | -439.516 | 1,452.755 | 1,230.711 | 1,167.281 | 933.965 | 1,079.958 | 769.632 | 447.423 | 305.217 | 204.726 |
| Net Income Ratio
| 0.202 | 0.13 | -0.257 | 0.402 | 0.366 | 0.403 | 0.391 | 0.456 | 0.434 | 0.367 | 0.329 | 0.296 |
| EPS
| 1.04 | 0.6 | -0.78 | 2.59 | 2.19 | 2.08 | 1.85 | 2.14 | 1.52 | 0.89 | 0.61 | 0.44 |
| EPS Diluted
| 1.04 | 0.6 | -0.78 | 2.59 | 2.19 | 2.08 | 1.85 | 2.14 | 1.51 | 0.88 | 0.59 | 0.44 |
| EBITDA
| 888.132 | 534.521 | -377.986 | 1,886.933 | 1,589.354 | 1,473.619 | 1,214.222 | 1,290.661 | 894.031 | 519.262 | 340.228 | 231.473 |
| EBITDA Ratio
| 0.292 | 0.205 | -0.221 | 0.522 | 0.473 | 0.509 | 0.509 | 0.544 | 0.505 | 0.426 | 0.367 | 0.334 |